Cargando…
Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?
Ductal carcinoma in situ (DCIS), especially in the era of mammographic screening, is a commonly diagnosed breast tumor. Despite the low breast cancer mortality risk, management with breast conserving surgery (BCS) and radiotherapy (RT) is the prevailing treatment approach in order to reduce the risk...
Autores principales: | Hahn, Ezra, Rodin, Danielle, Sutradhar, Rinku, Nofech-Mozes, Sharon, Trebinjac, Sabina, Paszat, Lawrence Frank, Rakovitch, Eileen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10297044/ https://www.ncbi.nlm.nih.gov/pubmed/37366916 http://dx.doi.org/10.3390/curroncol30060433 |
Ejemplares similares
-
Biological Markers Predictive of Invasive Recurrence in DCIS
por: Nofech-Mozes, Sharon, et al.
Publicado: (2008) -
Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies
por: Rakovitch, E., et al.
Publicado: (2018) -
Close or positive resection margins are not associated with an increased risk of chest wall recurrence in women with DCIS treated by mastectomy: a population-based analysis
por: Klein, Jonathan, et al.
Publicado: (2015) -
A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone
por: Rakovitch, Eileen, et al.
Publicado: (2015) -
Improving Therapeutic Ratios with the Oncotype DX® Ductal Carcinoma In Situ (DCIS) Score
por: Lalani, Nafisha, et al.
Publicado: (2017)